search
for
 About Bioline  All Journals  Testimonials  Membership  News


Journal of Postgraduate Medicine
Medknow Publications and Staff Society of Seth GS Medical College and KEM Hospital, Mumbai, India
ISSN: 0022-3859
EISSN: 0022-3859
Vol. 47, No. 1, 2001, pp. 66-67
Bioline Code: jp01023
Full paper language: English
Document type: Research Article
Document available free of charge

Journal of Postgraduate Medicine, Vol. 47, No. 1, 2001, pp. 66-67

 en Drug Review - Rofecoxib: A New Selective COX-2 Inhibitor
Rajadhyaksha VD, Dahanukar SA

Abstract

Pain is one of the commonest symptoms in many patients. The common causes of pain include musculoskelet al conditions like osteoarthritis and rheumatoid arthritis. (1) Nonsteroidal antiflammatory drugs (NSAIDS) are the first line drugs used in the treatment of such patients for alleviation pf pain.

The principal mechanism of action of NSAIDS is via the inhibition of cyclo-oxygenase enzyme (COX) involved in synthesis of prostaglandins. Decrease of prostaglandins can lead to decrease in pain and inflammation as they are one of the mediators involved in inflammation This enzyme exists in 2 isoforms - COX 1 and COX 2. The former is the constitutively expressed form of the enzyme, involved in prostaglandin synthesis in gastrointestinal, renal system and the platelets while the latter is induced by inflammation following inury. Recent studies confirm that inhibition of COX-2 - the other isoform is responsible for antiinflammatory effects of NSAIDS. (2) Rofecoxib is a newer COX-2 inhibitor that is developed for use in patients with osteoarthritis and/or acute pain and is now available in the Indian market.

 
© Copyright 2001 Journal of Postgraduate Medicine. Online full text also at http://www.jpgmonline.com
Alternative site location: http://www.jpgmonline.com

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil